CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,973 enrolled
Drug / intervention
Torsemide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03296813
NCT03296813Phase 3Completed
CompareCT.gov

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Duke University·interventional·Posted Sep 28, 2017·Updated Oct 16, 2025

In Brief

A Phase 3 clinical trial evaluating Torsemide and Furosemide for Heart Failure. Completed, enrolled 2,973 participants across 60 sites.

Detailed Summary

TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Yale University

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 28, 2017
Enrollment StartJul 11, 2018
Primary CompletionJul 29, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.8 years ago

Interventions

Torsemidedrug

Loop diuretic

Furosemidedrug

Loop diuretic